Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective long-term safety and efficacy evaluation of Cx401 in patients from FATT2
2009-014775-42Phase 3Completed
- Sponsor
- Cellerix S.A.
- Start
- Oct 2009
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of CX401 in anal fistula, sponsored by Cellerix S.A. Primary endpoint: Long-term safety (clinical and laboratory adverse events). Started Oct 2009; status: completed.
02
Drugs
CX401
03
Conditions
anal fistula
Beyond the preview
Go deeper on 2009-014775-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014775-42.